JOURNEY MEDICAL CORPORATION - COMMON STOCK

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

11 Jul 2024 16:05:39 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

15 May 2024 16:01:52 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

13 May 2024 16:01:47 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

07 May 2024 08:30:10 By Nasdaq GlobeNewswire

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

01 May 2024 16:01:30 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

25 Apr 2024 08:30:48 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

21 Mar 2024 16:01:27 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

18 Mar 2024 08:30:30 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

15 Mar 2024 08:30:01 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

13 Mar 2024 08:30:14 By Nasdaq GlobeNewswire

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

05 Jan 2024 08:30:12 By Nasdaq GlobeNewswire

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

02 Jan 2024 16:05:30 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 Dec 2023 08:00:51 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 Nov 2023 16:01:18 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 Oct 2023 08:30:12 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 Oct 2023 08:30:59 By Nasdaq GlobeNewswire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 Sep 2023 08:00:04 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 Aug 2023 16:01:33 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 Aug 2023 16:01:42 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 Jul 2023 08:30:00 By Nasdaq GlobeNewswire